Molecular and Cellular Biochemistry

, Volume 306, Issue 1–2, pp 105–113

Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom

  • Harry G. Preuss
  • Bobby Echard
  • Debasis Bagchi
  • Nicholas V. Perricone
  • Cun Zhuang



Intraperitoneal glucose tolerance (ipGTT) and insulin challenge (ICT) tests were implemented to evaluate whether a specific glycoprotein extract of maitake mushroom (Grifola frondosa) known as SX-fraction enhances insulin sensitivity in spontaneously hypertensive rats (SHR).


SHR were divided randomly into a control group, a group receiving the antidiabetic drug, pioglitazone, in their diet, and three groups consuming three different concentrations of SX-Fraction derived from maitake mushroom in their food. The response of circulating glucose and insulin concentrations was examined at different time periods during an ipGTT. The major action of exogenous insulin during the ipGTT occurred within a 15-min period following injection of regular insulin. Accordingly, hypoglycemic activity was evaluated in SHR with and without glucose challenge over a short time frame in the ICT.


Evidence gathered from the ipGTT and ICT tests suggests that the SX-fraction of Maitake in a proper dosage as well as pioglitazone enhance insulin sensitivity. Ingestion of SX-fraction produced a lower-circulating level of glucose after challenge despite no rise in circulating insulin. Compared to control, significantly lower-circulating glucose levels were seen in the groups consuming pioglitazone and higher doses of SX-fraction at 7.5 min after insulin challenge whether or not glucose was given concomitantly.


SHR in the pioglitazone and SX-fraction groups showed improved glucose tolerance despite no elevation of circulating insulin concentrations and showed enhanced sensitivity to exogenous insulin. Thus, a glycoprotein extract from Maitake mushroom (SX-fraction) should be considered as an alternative method for improving insulin sensitivity.


Maitake Natural products SX-fraction Insulin sensitivity Insulin resistance 


  1. 1.
    Preuss HG (1997) Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr 16:397–403PubMedGoogle Scholar
  2. 2.
    Preuss HG, Bagchi D, Clouatre D (2001) Insulin resistance; a factor in aging. In: Ghen MJ, Corso N, Joiner-Bey H, Klatz R, Dratz A (eds) The advanced guide to longevity medicine. Ghen, Landrum, SC, pp 239–250Google Scholar
  3. 3.
    Preuss HG, Bagchi D (2002) Nutritional therapy of impaired glucose tolerance and diabetes mellitus. In: Felix B (ed) Nutritional aspects and clinical management of chronic disorders and diseases. CRC Press, Boca Raton FL, pp 69–91Google Scholar
  4. 4.
    McCay C, Crowell M, Maynard L (1935) The effect of retarded growth upon the length of life and upon ultimate body size. J Nutr 10:63–79Google Scholar
  5. 5.
    Yu BP, Masoro EJ, Murata I, Bertrand HA, Lynd FT (1982) Lifespan study of SPF Fischer 344 male rats fed ad libitum or restricted diets: longevity, growth, lean body mass, and disease. J Gerontol 37:130–141PubMedGoogle Scholar
  6. 6.
    Hopkin K (1995) Aging in focus. Caloric restriction may put the brakes on aging. J NIH Res 7:47–50Google Scholar
  7. 7.
    Roth GS, Ingram DK, Lane MA (2001) Caloric restriction in primates and relevance to humans. Ann NY Acad Sci 928:305–315PubMedCrossRefGoogle Scholar
  8. 8.
    Masoro EJ, McCarter RJM, Katz MS, McMahan CA (1992) Dietary restriction alters characteristics of glucose fuel use. J Gerontol 47:B202–B208PubMedGoogle Scholar
  9. 9.
    Preuss HG (1998) Aging: relationship to insulin resistance. Maturity: Canada 1:12–14Google Scholar
  10. 10.
    Dilman VM, Anisimov VN (1980) Effect of treatment with phenformin, dyphenylhydantoin, or L-DOPA on lifespan and tumor incidence in C3H/Sn mice. Gerontology 26:241–245PubMedGoogle Scholar
  11. 11.
    Preuss HG, Montamarry S, Echard B, Scheckenbach R, Bagchi D (2001) Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. Mol Cell Biochem 223:95–102PubMedCrossRefGoogle Scholar
  12. 12.
    Preuss HG, Bagchi D, Bagchi M (2002) Protective effect of a novel niacin-bound chromium complex, a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X. In: Das DK, Ursini F (eds) Alcohol and wine in health and disease. Annals NY Acad Sci 957:250–259Google Scholar
  13. 13.
    Talpur N, Echard B, Yasmin D, Bagchi D, Preuss HG (2003) Effects of niacin-bound chromium, maitake mushroom fraction SX and a novel (-)-hydroxycitric acid extract on the metabolic syndrome in aged diabetic Zucker Fatty Rats. Molec Cell Biochem 252:369–377PubMedCrossRefGoogle Scholar
  14. 14.
    Anisimov VN, Semenchenko AV, Yashin AI (2003) Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 4:297–307PubMedCrossRefGoogle Scholar
  15. 15.
    Lane MA, Ingram DK, Roth GS (2002) The serious search for an anti-aging pill. Sci Am 287:36–41PubMedCrossRefGoogle Scholar
  16. 16.
    Ingram DK, Anson RM, de Cabo R, Mamczarz J, Zhu M, Mattison J, Lane MA, Roth GS (2004) Development of calorie restriction mimetics as a prolongevity strategy. Ann NY Acad Sci 1019:412–423PubMedCrossRefGoogle Scholar
  17. 17.
    Roth GS, Lane MA, Ingram DK (2005) Caloric restriction mimetics: the next phase. Ann NY Acad Sci 1057:365–371PubMedCrossRefGoogle Scholar
  18. 18.
    Campbell IW (1985) Metformin and the sulphonylureas: the comparative risk. Horm Metab Res Suppl. 15:105–111PubMedGoogle Scholar
  19. 19.
    Gale EA (2001) Lessons from the glitazones: a story of drug development. Lancet 357:1870–1875PubMedCrossRefGoogle Scholar
  20. 20.
    Isley WL (2003) Hepatotoxicity of thiazolidinediones. Expert Opin Drug Saf 2:581–586PubMedCrossRefGoogle Scholar
  21. 21.
    Mallick S (2004) Metformin induced acute pancreatitis precipitated by renal failure. Postgrad Med J 80:239–240PubMedCrossRefGoogle Scholar
  22. 22.
    Spiller HA, Sawyer TS (2006) Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 63:929–938PubMedCrossRefGoogle Scholar
  23. 23.
    Masubuchi Y (2006) Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 21:347–356PubMedCrossRefGoogle Scholar
  24. 24.
    Langenfeld MR, Forst T, Hohberg C (2005) Pioglitazone decreases carotid intima-media thickness independent of glycemic control in patients with type 2 diabetes mellitus. Circulation 111:2525–2531PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang G, Zhang BB (2005) Modulation of insulin signaling by insulin sensitizers. Biochem Soc Trans 33:358–361PubMedCrossRefGoogle Scholar
  26. 26.
    Lawrence JM, Reckless JB (2000) Pioglitazone. Int J Clin Pract 54:614–618PubMedGoogle Scholar
  27. 27.
    Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219–244PubMedGoogle Scholar
  28. 28.
    Bunag RD (1973) Validation in awake rats of a tail-cuff method measuring systolic pressure. J Appl Physiol 34:279–282PubMedGoogle Scholar
  29. 29.
    Dunnett C (1955) A multiple comparison procedure for comparing several treatments with control. J Am Statis Assoc 50:1096–1121CrossRefGoogle Scholar
  30. 30.
    Preuss MB, Preuss HG (1980) Effects of sucrose on the blood pressure of various strains of Wistar rats. Lab Invest 43:101–107PubMedGoogle Scholar
  31. 31.
    Chang S-L, Lin K-J, Lin R-T, Hung P-H, Lin J-G, Cheng J-T (2006) Enhanced insulin sensitivity using electroacupuncture on bilateral Zusanli acupoints (ST 36) in rats. Life Sci 79:967–971PubMedCrossRefGoogle Scholar
  32. 32.
    Williams CA, Shih MF, Taberner PV (2000) Effect of acute and sub-chronic administration of the imidazoline compound S 22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice. Gen Pharmacol 34:183–191PubMedCrossRefGoogle Scholar
  33. 33.
    Williams CA, Shih MF, Taberner PV (1999) A simple acute in vivo comparative test for sensitivity to insulin in the mouse. Horm Metab Res 31:580–582PubMedCrossRefGoogle Scholar
  34. 34.
    Kim DS, Kim TW, Kang JS (2004) Chromium picolinate supplementation improves insulin sensitivity in Goto-Kakizaki diabetic rats. J Trace Elem Med Biol 17:243–247PubMedCrossRefGoogle Scholar
  35. 35.
    Reaven GM, Hoffman BB (1987) A role for insulin in the aetiology and course of hypertension? Lancet ii:435–436CrossRefGoogle Scholar
  36. 36.
    Preuss HG, Gondal JA, Bustos E, Bushehri N, Lieberman S, Bryden NA, Polansky MM, Anderson RA (1995) Effect of chromium and guar on sugar-induced hypertension in rats. Clin Neph 44:170–177Google Scholar
  37. 37.
    Preuss HG, Grojec P, Lieberman S, Anderson RA (1997) Effects of different chromium compounds on sugar-induced hypertension. Clin Nephrol 47:325–330PubMedGoogle Scholar
  38. 38.
    Preuss HG, Anderson RA, Gondal J (1998) Comparative effects of chromium, vanadium, and Gymnema Sylvestre on sugar-induced blood pressure elevations in SHR. J Amer Coll Nutr 17:116–123Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Harry G. Preuss
    • 1
  • Bobby Echard
    • 1
  • Debasis Bagchi
    • 2
  • Nicholas V. Perricone
    • 3
  • Cun Zhuang
    • 4
  1. 1.Departments of Physiology, Medicine and PathologyGeorgetown University Medical CenterWashington, D.C.USA
  2. 2.Department of Pharmacy SciencesCreighton University Medical CenterOmahaUSA
  3. 3.Michigan State University College of Human MedicineEast LansingUSA
  4. 4.Maitake Products, IncEast RutherfordUSA

Personalised recommendations